Madison Dearborn 16亿美元收购Ikaria

2013年12月24日
Ikaria生物技术公司已经签约，将自己其下绝大部分业务以16亿美元的价格出售给Madison Dearborn Partners投资公司，但Ikaria公司仍保留了一些早期研发项目。根据协议Madison Dearborn Partners投资公司将获得Ikaria公司绝大部分的业务部门，其中包括目前已经获得FDA批准上市的药物Inomax，该药物主要用于治疗与阻塞性肺炎相关的低氧性呼吸衰竭。而目前Ikaria公司的共同拥有者New Mountain Capital, Arch Venture Partners, Venrock以及 5AM Ventures等投资公司也将通过这一协议获得16亿美元现金流。而这些财团将继续投资8000万美元用于Ikaria公司剩下的部门研发肺动脉高压等疾病的早期研究。

Ikaria公司出售的传言在今年十月份就已经甚嚣尘上，当时公司邀请了一系列财团为公司的三项临床研究解决资金问题。

Madison Dearborn to Acquire Ikaria in $1.6 Billion Deal
Madison Dearborn Partners LLC agreed to buy hospital therapy provider Ikaria Inc. in a transaction that values the company at $1.6 billion.

Existing shareholders of Hampton, New Jersey-based Ikaria, which include New Mountain Capital LLC, Arch Venture Partners, Venrock and 5AM Ventures Management LLC, will reinvest some of the proceeds into a 45 percent stake in the company, according to a statement today from New Mountain. The firms expect the deal to close in the first quarter of 2014.

Madison Dearborn has done at least five deals this year, according to data compiled by Bloomberg. The Chicago-based private-equity firm in April agreed to buy insurance brokerage National Financial Partners Corp. for about $1.3 billion including debt. Madison Dearborn has an investment in preventative care provider Sage Products LLC, and previous health-care stakes include Team Health Holdings LLC and Valitas Health Services Inc., according to the firm’s website.

Ikaria “is very well positioned for continued strong growth by virtue of its critical therapy, longstanding relationships with hospital administration and exceptional management team,” Tim Sullivan, a managing director at Madison Dearborn, said in a statement from the buyout firm.

Ikaria’s current investors formed the company in 2007 in a $670 million merger of gaseous drug maker INO Therapeutics and Ikaria, which was then a biotechnology firm. The company today sells Inomax, a drug-and-delivery system that uses nitric oxide to treat respiratory failure in newborn infants. Madison Dearborn plans to expand Ikaria’s business internationally, including in Japan, India and China, according to the firm’s statement.

Research Spinoff

As part of the transaction, Ikaria’s current shareholders will own a research division to be spun out of Ikaria that has $80 million to fund development of heart-treatment drugs and therapies, according to the statement from New Mountain.

Ikaria was advised by Credit Suisse Group AG and Morgan Stanley and received legal counsel from Fried Frank Harris Shriver & Jacobson LLP and Wilmer Cutler Pickering Hale & Dorr LLP. Madison Dearborn was advised by Barclays Plc, Goldman Sachs Group Inc. and Kirkland & Ellis LLP.